Although epidermal growth factor receptor (EGFR) inhibitors have revolutionary changes in the treatment landscape of lung cancer, drug resistance remains a formidable clinical challenge, with PTEN alterations emerging as pivotal players in this resistance narrative [95], [96]. This evidence concerns the gene EGFR and lung carcinoma.